SAFE Opioid Prescribing
During this session you will learn about ER/LA Opioids - Perspectives on Patient Assessment and Therapy Management, Goals of Therapy, Monitoring and Patient Education of ER/LA Opioids, Assessing ER/LA Opioid Products: Similarities and Differences Prescribers Need to Know. This educational activity is supported by an independent educational grant from the Extended-Release/Long-Acting Opioid Analgesic REMS Program Companies. Please see http://ce.er-la-opioidrems.com/IwgCEUI/rems/pdf/List_of_RPC_Companies.pdf for a listing of REMS Program Companies. This activity is intended to be fully compliant with the Extended-Release/Long-Acting Opioid Analgesics REMS education requirements issued by the US Food & Drug Administration.
Speaker’s Bureau for Allergan, Inc., Amgen Inc., BioDelivery Sciences International, Inc., Daiichi Sankyo, Inc., and Depomed, Inc. Advisory Board member for Braeburn Pharmaceuticals, Inc., Depomed, Inc., Kaléo Pharma, Pfizer Inc., Quest Pharmaceuticals, Inc., and Teva Pharmaceuticals. Consultant for Nevro and Vertex Pharmaceuticals Incorporated. Contracted Research for Grünenthal GmbH and Vertex Pharmaceuticals Incorporated. Ownership Interest in Depomed, Inc. and Pfizer Inc.
Speakers Bureau member for Collegium Pharmaceutical, Inc. Depomed, Inc., Daiichi Sankyo, Inc., Purdue Pharma L.P, and Teva Pharmaceuticals. Advisory Board member for AstraZeneca Pharmaceuticals LP, Collegium Pharmaceutical, Inc. Depomed, Inc., Daiichi Sankyo, Inc., and Purdue Pharma L.P. Ownership Interest in Cara Therapeutics.
Speakers Bureau member for AstraZeneca Pharmaceuticals LP, Collegium Pharmaceutical, Inc., Daiichi Sankyo, Inc., Purdue Pharma L.P., and Salix Pharmaceuticals Inc. Advisory Board member for Depomed, Inc. Consultant BioDelivery Sciences International, Inc., Nektar Therapeutics, Pernix Therapeutics, and Quest Diagnostics.
Speakers Bureau member for Collegium Pharmaceutical Inc. Advisory Board member for Collegium Pharmaceutical, Inc., Daiichi Sankyo, Inc., Pernix Therapeutics, and Pfizer Inc. Has ownership interests in BioSpecifics Technologies Corp., Collegium Pharmaceutical, Galena Biopharma and Johnson & Johnson.
Non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
REMS Program Companies
Miller Medical Communications, LLC
The opinions, ideas, and recommendations expressed in this educational activity are those of the faculty only and are not necessarily endorsed by, nor do they necessarily reflect, those of their affiliated institutions, pmiCME, pmiCME Advisory Boards and Consultants, DBC Pri-Med, LLC.
Clinical judgment must guide each clinician in weighing the possible risks, benefits, or contraindications of any diagnostics, interventions or treatments discussed. Clinicians should review manufacturers’ product information and consider these with the recommendations of other authorities when applying the assessment and/or clinical management strategies discussed in this activity to the care of their patients.
pmiCME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of pmiCME to develop and present educational activities that are timely, fair-balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome your comments about how to better serve your needs.
pmiCME Accredited Provider
Pri-Med programs are owned and operated by DBC Pri-Med, LLC, a division of Diversified Communications, Inc. pmiCME, the accredited division of Pri-Med, is accredited with commendation by the ACCME and approved as a provider of continuing education by the AANP. pmiCME is the accredited provider for this activity.
Disclosures and Conflict of Interest
pmiCME requires all individuals in a position to influence educational content for pmiCME-certified CME/CE activities to disclose relevant personal financial relationships with commercial interests prior to contributing to its educational activities. pmiCME assesses disclosed relationships and follows a defined process to resolve real or implied conflicts to ensure, to the best of its ability, that all educational content is free of commercial bias. Financial disclosures are listed in the activity syllabus and will also be printed on the slides and announced at the start of each presentation.
Discussion of Off-Label Uses and Investigational Products
During the course of their presentations, the faculty may mention uses of products that have not been approved in the United States for the indication(s) being discussed. All presenters are instructed to notify participants when they are discussing unapproved uses or investigational agents. In addition, specific slides will include notation of the off-label use or investigational agent being discussed. Views presented related to unapproved uses of products are solely those of the presenter(s) and are not endorsed by pmiCME or DBC Pri-Med, LLC.
Questions? If you have questions about this activity, please email email@example.com or call (877) 477-4633.